Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab vs Dexamethasone in Severe COVID-19
NCT04519385Completed
- Sponsor
- South Valley University
- Start
- Mar 2020
- Primary completion
- Jul 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Randomised, open-label trial of tocilizumab in COVID-19 pneumonia (2 arms), sponsored by South Valley University. Primary endpoint: Proportion of participants with Overall Survival at 14 days. Started Mar 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04519385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04519385.